Delphi Management Partners VIII’s Mereo BioPharma MREO Stock Holding History

Delphi Management Partners VIII’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$621K	Hold	256,734	–	–	0.45%	4
2021 Q2	$814K	Hold	256,734	–	–	0.64%	4
2021 Q1	$865K	Hold	256,734	–	–	0.6%	5
2020 Q4	$919K	Buy	+256,734	New	+$643K	0.6%	5
2019 Q4	$842K	Buy	+256,734	New	+$656K	0.66%	5

Other funds holding MREO

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Delphi Management Partners VIII's MREO Position: Q3 2021 in Review

Delphi Management Partners VIII held its Mereo BioPharma (MREO) position steady in Q3 2021 at 256,734 shares worth $621K. The position accounts for 0.45% of the portfolio, ranked #4.

Delphi Management Partners VIII first reported a position in MREO in Q4 2019 and has held it in 5 quarters since. The position peaked at $919K in Q4 2020. 63 funds tracked by Wall St. Rank hold MREO as of Q3 2021.

Delphi Management Partners VIII held 256,734 shares of Mereo BioPharma worth $621K as of Q3 2021.
Delphi Management Partners VIII left its Mereo BioPharma share count unchanged in Q3 2021.
Mereo BioPharma made up 0.45% of Delphi Management Partners VIII's portfolio in Q3 2021, its #4 holding.
Delphi Management Partners VIII first reported a position in Mereo BioPharma in Q4 2019 and has held it in 5 quarters since.
Delphi Management Partners VIII's Mereo BioPharma position peaked at $919K in Q4 2020.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2021.

Based on Delphi Management Partners VIII's 13F filing for Q3 2021, filed 15 Nov 2021.